NCT05336383 2026-04-15
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT04268199 2025-12-15
EASE
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT06947083 2025-12-03
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07106671 2025-08-06
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06863584 2025-03-07
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05597345 2025-02-10
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Phase 2 Recruiting
NCT06430736 2024-07-08
PRONTO
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT05248633 2024-06-05
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04935684 2023-03-01
TMF-Allo
University Hospital, Clermont-Ferrand
Phase 2 Recruiting